R. Hawkins, S. Pingree, D. V. Bogaert, Helene McDowell, D. Jarrard, C. Carmack, A. Salner
{"title":"The impact of combining human and online supportive resources for prostate cancer patients","authors":"R. Hawkins, S. Pingree, D. V. Bogaert, Helene McDowell, D. Jarrard, C. Carmack, A. Salner","doi":"10.12788/JCSO.0330","DOIUrl":"https://doi.org/10.12788/JCSO.0330","url":null,"abstract":"","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49294702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Whitney A. Welch, Gillian R Lloyd, E. Awick, J. Siddique, E. McAuley, Siobhan M. Phillips
Physical activity has numerous physical, mental, and psychosocial bene ts for cancer survivors, such as a reduction in the risk of mobility disability, depression, and anxiety, and improved patient quality of life.1,2 In addition, higher levels of physical activity are associated with reduced cancerspeci c and all-causes mortality as well as cancerspeci c outcomes including reduced risk of cancer progression and recurrence and new primary cancers.3-5 However, fewer than one-third of cancer survivors are meeting government and cancerspeci c recommendations of 150 minutes a week of moderate to vigorous physical activity (MPVA; ≥3 metabolic equivalents [METs]).6,7 Growing evidence also demonstrates a signi cant association between higher levels of sedentary behavior and many deleterious health eects after cancer, including an increased risk for decreased physical functioning and development of other chronic diseases such as cardiovascular disease or diabetes.8 Distinct from physical activity, sedentary behavior is de ned as any waking activity resulting in low levels of energy expenditure (≤1.5 METs) while in a seated or reclined position.9 Increased sedentary behavior, even when controlling for moderate and vigorous physical activity (MVPA), is associated with poor quality of life and increased all-cause mortality in cancer survivors.10,11 Given the associations
{"title":"Measurement of physical activity and sedentary behavior in breast cancer survivors","authors":"Whitney A. Welch, Gillian R Lloyd, E. Awick, J. Siddique, E. McAuley, Siobhan M. Phillips","doi":"10.12788/JCSO.0387","DOIUrl":"https://doi.org/10.12788/JCSO.0387","url":null,"abstract":"Physical activity has numerous physical, mental, and psychosocial bene ts for cancer survivors, such as a reduction in the risk of mobility disability, depression, and anxiety, and improved patient quality of life.1,2 In addition, higher levels of physical activity are associated with reduced cancerspeci c and all-causes mortality as well as cancerspeci c outcomes including reduced risk of cancer progression and recurrence and new primary cancers.3-5 However, fewer than one-third of cancer survivors are meeting government and cancerspeci c recommendations of 150 minutes a week of moderate to vigorous physical activity (MPVA; ≥3 metabolic equivalents [METs]).6,7 Growing evidence also demonstrates a signi cant association between higher levels of sedentary behavior and many deleterious health eects after cancer, including an increased risk for decreased physical functioning and development of other chronic diseases such as cardiovascular disease or diabetes.8 Distinct from physical activity, sedentary behavior is de ned as any waking activity resulting in low levels of energy expenditure (≤1.5 METs) while in a seated or reclined position.9 Increased sedentary behavior, even when controlling for moderate and vigorous physical activity (MVPA), is associated with poor quality of life and increased all-cause mortality in cancer survivors.10,11 Given the associations","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48117882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical presentation, diagnosis, and management of typical and atypical bronchopulmonary carcinoid","authors":"Hamza Hashmi","doi":"10.12788/JCSO.0365","DOIUrl":"https://doi.org/10.12788/JCSO.0365","url":null,"abstract":"","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43749881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This past year will likely be remembered as one of breakthrough advances in reducing the burden of cancer, with some landmark “rsts” coming out of the US Food and Drug Administration (FDA). Among the notable approvals were the rst CART [chimeric antigen receptor T-cell] immunotherapies – tisagenlecleucel (Kymriah) for B-cell precursor acute lymphoblastic leukemia, and axicabtagene ciloleucel (Yescarta) for relapsed or refractory large B-cell lymphoma; the rst US-approved biosimilar for cancer, bevacizumab-awwb (Mvasi) for multiple types of cancer; and rst-time approvals for neratinib (Nerlynx) as an extended adjuvant therapy for early-stage human epidermal growth factor receptor 2 (HER2)-overexpressed/amplied breast cancer, and avelumab (Bavencio) for the treatment of metastatic Merkel cell carcinoma. But our excitement about those advances will undoubtedly be tempered by the continued challenges in expanding access to better quality health care, piloting more eective payment models, and consolidating delivery systems. Our excitement has also been tempered by the rapid rise in the cost of eective biologic, immunologic, and targeted therapies. With the approval of trastuzumab-dkst (Ogivri), the rst targeted biosimilar for HER2-positive breast and gastrointestinal cancers, we can look forward to price decreases possibly in the 20%-30% range over time from a targeted therapy with remarkable clinical ecacy. We know that approved biosimilars have demonstrated clinical ecacy along with similar minor biologic diversity that is also seen in the reference biologic.1 We can also hope that increasing competition among biosimilar and reference compounds will lead to improvements in production methodologies that can allow further price reductions so that even more patients can gain access to these highly eective therapies. In addition, the rst FDA approval for the next-generation sequencing (NGS) FoundationOne proling test and the rapid announcement by the Centers for Medicare & Medicaid Services (CMS) that it will cover the cost of that testing brings us a step closer to knowing which patients most likely will or won’t benet from costly and toxic targeted therapies. Along with the many clinical trials studying which mutations predict which ecacies of individual or combinations of targeted agents, the approval and CMS coverage policy will help us improve value to our patients; when we can recommend the most benecial therapies and avoid futile ones. Finally, the approval for the DigniCap Scalp Cooling System for patients on chemotherapy for all solid tumors is of great importance. Pending coverage availability, it may in¦uence some patients to get chemotherapy they might otherwise have forgone to avoid hair loss (see also pp. e346-e348).
{"title":"Cancer care in 2017: the promise of more cures with the challenges of an unstable health care system","authors":"L. Bosserman","doi":"10.12788/JCSO.0373","DOIUrl":"https://doi.org/10.12788/JCSO.0373","url":null,"abstract":"This past year will likely be remembered as one of breakthrough advances in reducing the burden of cancer, with some landmark “rsts” coming out of the US Food and Drug Administration (FDA). Among the notable approvals were the rst CART [chimeric antigen receptor T-cell] immunotherapies – tisagenlecleucel (Kymriah) for B-cell precursor acute lymphoblastic leukemia, and axicabtagene ciloleucel (Yescarta) for relapsed or refractory large B-cell lymphoma; the rst US-approved biosimilar for cancer, bevacizumab-awwb (Mvasi) for multiple types of cancer; and rst-time approvals for neratinib (Nerlynx) as an extended adjuvant therapy for early-stage human epidermal growth factor receptor 2 (HER2)-overexpressed/amplied breast cancer, and avelumab (Bavencio) for the treatment of metastatic Merkel cell carcinoma. But our excitement about those advances will undoubtedly be tempered by the continued challenges in expanding access to better quality health care, piloting more eective payment models, and consolidating delivery systems. Our excitement has also been tempered by the rapid rise in the cost of eective biologic, immunologic, and targeted therapies. With the approval of trastuzumab-dkst (Ogivri), the rst targeted biosimilar for HER2-positive breast and gastrointestinal cancers, we can look forward to price decreases possibly in the 20%-30% range over time from a targeted therapy with remarkable clinical ecacy. We know that approved biosimilars have demonstrated clinical ecacy along with similar minor biologic diversity that is also seen in the reference biologic.1 We can also hope that increasing competition among biosimilar and reference compounds will lead to improvements in production methodologies that can allow further price reductions so that even more patients can gain access to these highly eective therapies. In addition, the rst FDA approval for the next-generation sequencing (NGS) FoundationOne proling test and the rapid announcement by the Centers for Medicare & Medicaid Services (CMS) that it will cover the cost of that testing brings us a step closer to knowing which patients most likely will or won’t benet from costly and toxic targeted therapies. Along with the many clinical trials studying which mutations predict which ecacies of individual or combinations of targeted agents, the approval and CMS coverage policy will help us improve value to our patients; when we can recommend the most benecial therapies and avoid futile ones. Finally, the approval for the DigniCap Scalp Cooling System for patients on chemotherapy for all solid tumors is of great importance. Pending coverage availability, it may in¦uence some patients to get chemotherapy they might otherwise have forgone to avoid hair loss (see also pp. e346-e348).","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45607541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"2017 notches up some landmark approvals","authors":"D. Mintzer","doi":"10.12788/JCSO.0375","DOIUrl":"https://doi.org/10.12788/JCSO.0375","url":null,"abstract":"","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45635819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Skin adnexal tumors (SAT) are rare tumors that make up about 1%-2% of all cutaneous malignancies. ey represent a various group of benign and malignant tumors that arise from skin adnexal epithelial structures: hair follicle, pilosebaceous unit, and apocrine or eccrine sweat glands. Although this derivation provides a practical basis for classication, some tumors may exhibit a mixed or more than one line of dierentiation, rendering precise classication of those neoplasms dicult, and such cases should be categorized according to prevailing phenotype. In this report, we present a patient with metastatic eccrine carcinoma. Clinical experience for metastatic disease treatment is derived from a few reports, and there are no universal treatment guidelines. Given the few reported cases and the absence of randomized clinical trials for these patients, it is important to collect clinical experiences.
{"title":"Metastatic eccrine carcinoma with stomach and pericardial involvement","authors":"Ahmed T Ahmed","doi":"10.12788/JCSO.0351","DOIUrl":"https://doi.org/10.12788/JCSO.0351","url":null,"abstract":"Skin adnexal tumors (SAT) are rare tumors that make up about 1%-2% of all cutaneous malignancies. ey represent a various group of benign and malignant tumors that arise from skin adnexal epithelial structures: hair follicle, pilosebaceous unit, and apocrine or eccrine sweat glands. Although this derivation provides a practical basis for classication, some tumors may exhibit a mixed or more than one line of dierentiation, rendering precise classication of those neoplasms dicult, and such cases should be categorized according to prevailing phenotype. In this report, we present a patient with metastatic eccrine carcinoma. Clinical experience for metastatic disease treatment is derived from a few reports, and there are no universal treatment guidelines. Given the few reported cases and the absence of randomized clinical trials for these patients, it is important to collect clinical experiences.","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48020903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval","authors":"J. D. Lartigue","doi":"10.12788/JCSO.0382","DOIUrl":"https://doi.org/10.12788/JCSO.0382","url":null,"abstract":"","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48898046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prostate cancer treatments are associated with various physical after-e ects, including urinary, sexual, and bowel symptoms.1 ese after-e ects can have an impact on survivors’ healthrelated quality of life (HRQoL).2 Pharmaceutical and surgical interventions are available to manage or ameliorate many of these after-e ects (eg, sildena l citrate taken during and after radiotherapy improves sexual function),3 and their receipt has a positive impact on HRQoL.4 However, studies of clinicians suggest that such interventions may not be used widely.5,6 Patientreported data on this topic is lacking. erefore, we investigated the use of supportive medications and interventions in this population-based study of prostate cancer survivors. Methods e PiCTure (Prostate Cancer Treatment, Your Experience) study methods have been described elsewhere.7 Briey, 6,559 prostate cancer survivors 2-15 years after diagnosis (diagnosed during January 1, 1995-March 31, 2010, and alive in November 2011), identi ed from population-based cancer registries in the Republic of Ireland and Northern Ireland, were invited to complete a postal survey. Information was sought on after-e ects (incontinence, impotence, gynaecomastia, hot ashes/sweats, bowel problems, depression) that had been experienced at any time after treatment. For each after-e ect, men were asked if they had received any medication or interventions to alleviate symptoms, and, if so, what they had received; examples of common interven-
{"title":"Supportive medications and interventions received by prostate cancer survivors: results from the PiCTure study","authors":"F. Drummond, A. Gavin, L. Sharp","doi":"10.12788/JCSO.0384","DOIUrl":"https://doi.org/10.12788/JCSO.0384","url":null,"abstract":"Prostate cancer treatments are associated with various physical after-e ects, including urinary, sexual, and bowel symptoms.1 ese after-e ects can have an impact on survivors’ healthrelated quality of life (HRQoL).2 Pharmaceutical and surgical interventions are available to manage or ameliorate many of these after-e ects (eg, sildena\u0085l citrate taken during and after radiotherapy improves sexual function),3 and their receipt has a positive impact on HRQoL.4 However, studies of clinicians suggest that such interventions may not be used widely.5,6 Patientreported data on this topic is lacking. erefore, we investigated the use of supportive medications and interventions in this population-based study of prostate cancer survivors. Methods e PiCTure (Prostate Cancer Treatment, Your Experience) study methods have been described elsewhere.7 Briey, 6,559 prostate cancer survivors 2-15 years after diagnosis (diagnosed during January 1, 1995-March 31, 2010, and alive in November 2011), identi\u0085ed from population-based cancer registries in the Republic of Ireland and Northern Ireland, were invited to complete a postal survey. Information was sought on after-e ects (incontinence, impotence, gynaecomastia, hot ashes/sweats, bowel problems, depression) that had been experienced at any time after treatment. For each after-e ect, men were asked if they had received any medication or interventions to alleviate symptoms, and, if so, what they had received; examples of common interven-","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49198010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
For patients with cancer, acknowledgment of mental and emotional distress is critically important when developing and implementing a treatment plan. e psychosocial distress associated with cancer diagnosis and treatment can have an impact on a patient’s quality of life, inuence a patient’s ability to adhere to treatment regimens, and increase cost of care.1-4 Rates of depression have been reported to range from 8%-36%, with a 29% risk of anxiety in cancer patients.5, 6 Emotional distress is linked to increased hopelessness about their cancer diagnosis, increased issues with chronic pain, and negative treatment outcomes.7 Timely screening of psychosocial distress at the rst clinical visit enables providers to make appropriate referrals to resources early in their course of treatment; however, referrals to psychosocial interventions remain infrequent nationwide in the United States.8 ere is some evidence of a di erential impact of cancer on mental health diagnoses between racial/ethnic groups; however, results are not entirely consistent across studies. Using the Kessler Pyschological Distress Scale (K6) score, Alcala and colleagues found that cancer was more detrimental to mental health for black patients than for nonHispanic white patients.9 Black breast cancer survivors have also been shown to be more likely to stop working during the early phases of their treatment, indicating that they and their physicians need to take steps to minimize long-term employment consequences.10 However, in a study of women with breast cancer, black women reported fewer depressive symptoms than did non-Hispanic whites.11 e American College of Surgeons’ Commission on Cancer (ACS CoC) developed a set of Continuum of Care standards in 2012, including the implementation of psychosocial distress screening for patients with cancer. Since 2015, all accredited cancer programs are now required to evaluate these patients for signs of distress during at least
{"title":"Differences in psychosocial stressors between black and white cancer patients","authors":"L. Hinyard","doi":"10.12788/jcso.0366","DOIUrl":"https://doi.org/10.12788/jcso.0366","url":null,"abstract":"For patients with cancer, acknowledgment of mental and emotional distress is critically important when developing and implementing a treatment plan. e psychosocial distress associated with cancer diagnosis and treatment can have an impact on a patient’s quality of life, inuence a patient’s ability to adhere to treatment regimens, and increase cost of care.1-4 Rates of depression have been reported to range from 8%-36%, with a 29% risk of anxiety in cancer patients.5, 6 Emotional distress is linked to increased hopelessness about their cancer diagnosis, increased issues with chronic pain, and negative treatment outcomes.7 Timely screening of psychosocial distress at the rst clinical visit enables providers to make appropriate referrals to resources early in their course of treatment; however, referrals to psychosocial interventions remain infrequent nationwide in the United States.8 ere is some evidence of a di erential impact of cancer on mental health diagnoses between racial/ethnic groups; however, results are not entirely consistent across studies. Using the Kessler Pyschological Distress Scale (K6) score, Alcala and colleagues found that cancer was more detrimental to mental health for black patients than for nonHispanic white patients.9 Black breast cancer survivors have also been shown to be more likely to stop working during the early phases of their treatment, indicating that they and their physicians need to take steps to minimize long-term employment consequences.10 However, in a study of women with breast cancer, black women reported fewer depressive symptoms than did non-Hispanic whites.11 e American College of Surgeons’ Commission on Cancer (ACS CoC) developed a set of Continuum of Care standards in 2012, including the implementation of psychosocial distress screening for patients with cancer. Since 2015, all accredited cancer programs are now required to evaluate these patients for signs of distress during at least","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42295521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Brigatinib approval yields additional treatment options for crizotinib-resistant, ALK-positive NSCLC patients","authors":"J. D. Lartigue","doi":"10.12788/JCSO.0380","DOIUrl":"https://doi.org/10.12788/JCSO.0380","url":null,"abstract":"","PeriodicalId":75058,"journal":{"name":"The Journal of community and supportive oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45776349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：